A Randomized, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2015

At a glance

  • Drugs Bifeprunox (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Abbott Healthcare Products
  • Most Recent Events

    • 16 Jun 2009 Additional locations identified as reported by ClinicalTrials.gov.
    • 21 Mar 2008 Status changed from suspended to discontinued as reported by ClinicalTrials.gov
    • 14 Feb 2008 The expected completion date for this trial is now 1 Jan 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top